Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning

NCT06152900 | Completed FDA Device

• 1 other identifier: AFL19006
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 2

Brief Summary

Open-label, baseline-controlled, multi-center study evaluating an electrical muscle stimulation system for circumferential reduction and muscle toning. The study will enroll up to 100 subjects desiring circumferential reduction and muscle toning. Each subject will receive up to 12 bi-weekly treatments over a 6-week period. Follow Up Visits planned for 2, 30- and 90-days post treatment. Measurement outcomes will be compared to baseline.

Conditions

Fat Necrosis; Muscle Stimulation

Outcome Measures

Primary Outcomes (1)

• Photographic Evaluation

  Photographic evaluation by an independent, blinded reviewer with correct identification of pre-treatment baseline images when compared to post-treatment images taken at follow up visits (48 hours, 30 days, 90 days).Results will be reported as a % of the correctly identified post treatment photographs chosen per Blinded Reviewer. An average of the % of the correctly identified post treatment photographs chosen by Blinded Reviewer will be calculated and used to determine efficacy.

  Baseline, 48-hours post treatment, 30-day FU, 90-day FU

Secondary Outcomes (4)

• Circumferential Reduction

  Baseline, 30-day FU, 90-day FU

• Subject Satisfaction

  30-day FU, 90-day FU

• Global Aesthetic Improvement Scale

  30-day FU, 90-day FU

• Muscle Strength

  Baseline, 30-day FU, 90-day FU

Study Arms (1)

Treatment Arm

EXPERIMENTAL

All subjects enrolled in the study will be placed into the treatment arm of the study, to be treated by the Accufit device.

Device: Accufit

Interventions

Accufit DEVICE

Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation. Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle.

Also known as: ME Sys*STIM 240

Treatment Arm

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to read, understand and voluntarily provide written informed consent.
• Healthy male or female, ≥ 18 years to 65 years of age seeking treatment for improved muscle strength and muscle toning in their core and extremities.
• Subject is determined to be physically fit and agrees to not making any major changes in their diet or lifestyle during the study.
• Able and willing to comply with the treatment/follow-up schedule and requirements.
• Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study as well as have a negative Urine Pregnancy test at baseline.

You may not qualify if:

• Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in the last 6 months.
• Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
• History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications, 6 months prior to and during the study.
• History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
• Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or premalignant pigmented lesions.
• Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone in the treatment area.
• Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
• Poor skin quality (severe laxity).
• Abdominal wall, muscular abnormality or hernia on physical examination.
• As per the investigator's discretion, any physical or mental condition which may make it unsafe for the subject to participate.
• Subjects unwilling or unable to adhere to all study requirements for treatment and follow-up.
• Investigator may exclude any subject at any time at his/her discretion.

Sponsors & Collaborators

• LUTRONIC Corporation: lead

Study Sites (2)

Lutronic US Headquarters

Billerica, Massachusetts, 01821, United States

Location

Union Square Dermatology

New York, New York, 10003, United States

Location

MeSH Terms

Conditions

Fat Necrosis

Condition Hierarchy (Ancestors)

Necrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 22, 2023
• First Posted: December 1, 2023
• Study Start: October 5, 2021
• Primary Completion: November 20, 2022
• Study Completion: November 20, 2023
• Last Updated: December 1, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)